ZURICH, April 29 (Reuters) - Contract drug manufacturer Lonza plans to double Swiss production capacity for Moderna's COVID-19 vaccine, helping the U.S. drugmaker boost total output to as many as 3 billion doses in 2022. (Reporting by John Miller Editing by Riham Alkousaa)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
519.6 CHF | +1.09% | -1.55% | +46.90% |
Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
Apr. 18 | Lonza Finance Launches EUR1 Billion 12-Year Euro Bond | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.90% | 40.62B | |
+25.69% | 48.09B | |
-3.46% | 40.43B | |
-6.20% | 28.36B | |
+9.17% | 24.89B | |
-20.42% | 19.01B | |
+28.07% | 12.09B | |
+0.17% | 11.88B | |
-1.24% | 11.8B | |
+19.33% | 11.45B |
- Stock Market
- Equities
- LONN Stock
- News Lonza Group AG
- Lonza : Switzerland's Lonza to boost production for Moderna COVID-19 vaccine